A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
about
Adefovir dipivoxil versus other antiviral drugs for chronic hepatitis BAdefovir dipivoxil for chronic hepatitis BDirect acting antivirals for the treatment of chronic viral hepatitisIn vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracilCross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virusA randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucksInhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Diagnosis and management of pre-core mutant chronic hepatitis B.Evolving therapies for the treatment of chronic hepatitis B virus infection.Chronic hepatitis B: current and future treatment options.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.Adefovir dipivoxil in chronic hepatitis B infection.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.Development of a novel mouse model to evaluate drug candidates against hepatitis B virus.BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005).[The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review].Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus.
P2860
Q24234842-255A9F10-A958-4A80-BB5A-775E44D88AC8Q24234931-4D07194D-DAB1-4823-9415-BEE31F3D9576Q27022216-7D3BE786-AF60-4BE3-B449-D0A03ACEE112Q28345952-E46DB851-9581-4687-BF87-B5FE383A3005Q28365198-BD53632C-B962-416B-AC2D-76C56012479CQ33962669-8ED3F9CB-CFC0-489F-BF5B-6EB6347D5D3AQ33983079-3E8E2D6E-9991-4A82-AE11-921CF531CD67Q34105204-A6619769-A85E-4A34-BF9B-7F6333B31C7CQ34368364-23370192-59E6-4B38-8486-4A32BC5F63E4Q34519117-38E8C7A0-EB5A-4FFB-8DAF-988800300461Q34687438-E4ECB7A6-4A77-4BFB-B986-F6236E4BC08FQ35558801-D1C46F47-EA04-4EAE-AD31-9C3EAAED16FFQ35917125-686E7ECD-64C2-4298-AFC9-64C688D700C9Q35925551-955FA2BB-DD3F-4F96-885D-1C69FB30C8BFQ35987869-55825D78-B509-418C-9E2F-944D52265AA6Q36957087-77075839-4E59-42A7-A437-64F8004D1C62Q38665203-093301BE-EBDF-4C8C-BAB4-F6E6248AE855Q39277056-C100D48C-96FE-4C15-A900-2542E872E377Q39652342-0B4300DD-9F2A-44BB-87A7-2833ADE2C30FQ40073982-997B9403-C7DA-4672-B0BD-D67F812BC426Q40406133-53ACA9BB-A994-4888-9D03-E8EA5FB2023BQ42922840-099B3B9A-47D1-4EE0-B906-2C8C72BEB1A1Q44738460-08313904-F2A4-42C5-9168-9A53BFBA2071Q45163318-0492AA6E-56C6-4567-BDF2-9C9D125284DDQ45164423-F733673E-65CB-49FE-9AF9-E7489A00FDECQ45408066-40F824E4-6675-486B-B015-C3E5FF2C0515Q45711101-F3C2C059-8557-4134-9A5F-1394EBCDA6E5
P2860
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@en
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@nl
type
label
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@en
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@nl
prefLabel
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@en
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@nl
P2093
P2860
P1476
A placebo-controlled phase I/I ...... c hepatitis B virus infection.
@en
P2093
A M Newell
I M Murray-Lyon
I V Weller
K B Chopra
M R Nelson
R J Gilson
R S Tedder
P2860
P304
P356
10.1046/J.1365-2893.1999.00182.X
P577
1999-09-01T00:00:00Z